# Lamivudine and Adefovir to Treat Chronic Hepatitis B

> **NCT00023309** · PHASE2 · COMPLETED · sponsor: **National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)** · enrollment: 41 (actual)

## Conditions studied

- HBV (Hepatitis B Virus)
- Hepatitis B
- Hepatitis

## Interventions

- **DRUG:** Lamivudine and adefovir
- **DRUG:** Adefovir alone

## Key facts

- **NCT ID:** NCT00023309
- **Lead sponsor:** National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-08
- **Primary completion:** 2010-04
- **Final completion:** 2013-08
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2016-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00023309

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00023309, "Lamivudine and Adefovir to Treat Chronic Hepatitis B". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00023309. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*